FDA Approval: FLAURA2, First Line Osimertinib Plus Chemotherapy

FDA Approval: FLAURA2, First Line Osimertinib Plus Chemotherapy for EGFR NSCLC

Listen now

Description

In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion on the FLAURA2 study and changes in the first line treatment of EGFR NSCLC with guests Dr. Pasi Jänne and Dr. Marcelo Corassa. FLAURA2 was first presented at the 2023 WCLC in Singapore by Dr. Jänne.

More Episodes

See all »

KRAS in NSCLC: Beyond G12C

In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses KRAS mutant non-small cell lung cancer, other than G12C. This form of lung cancer varies by geography and incidence. KRAS mutations were once thought undruggable, but KRAS inhibitors are now available. However, not all...

Published 04/30/24

FDA Approval: Adjuvant Alectinib for Resected NSCLC

In the wake of the FDA's approval of alectinib for resected non-small cell lung cancer, Lung Cancer Considered host Dr. Narjust Florez and Dr. Benjamen Solomon discuss this development and take a deeper look at the ALINA trial, which played an important role in the drug's approval.

Published 04/18/24

Lung Cancer Considered

Published 04/18/24